# Altay Therapeutics

> Develops oral small-molecule transcription-factor inhibitors, led by DX5057 for FSHD.

## Why it is interesting

A $37 million Series A finances the transition from preclinical DUX4 biology into human testing, offering a different delivery approach from RNA therapeutics.

## Profile

- **Latest funding:** Series A — US$37 million (October 14, 2026)
- **Latest known valuation:** Undisclosed (October 14, 2026)
- **Total disclosed equity funding:** $37M
- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-10-15T07:21:45Z
- **Latest funding investors:** Sound Bioventures, HealthCap, Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital, Global BioAccess Fund

## Funding history

- Series A · US$37 million · October 14, 2026
  Source: https://www.healthcap.eu/media/altay-therapeutics-closes-37-million-series-a-financing-to-advance-first-oral-dux4-inhibitor-for-fshd-into-the-clinic/

## Investors in our directory

- https://venturecapitaltracker.com/fund/sound-bioventures
- https://venturecapitaltracker.com/fund/healthcap
- https://venturecapitaltracker.com/fund/fountain-healthcare-partners
- https://venturecapitaltracker.com/fund/pappas-capital

## Related articles

- https://venturecapitaltracker.com/altay-therapeutics-37m-series-a-oral-fshd

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/altay-therapeutics